Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 23

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 23
---
 Compensation (“ASC 718”), rather than the amounts paid or realized by the named individual. We provide information regarding the assumptions used to calculate grant date fair value of our stock options in Note 14 to our audited consolidated financial statements filed with our Annual Report on Form 10-K for the year ended December 31, 2024. For 2024 option awards, the number of option shares was determined by dividing the target economic value of each individual’s stock option award by the corresponding ASC 718 fair value using a Black-Scholes valuation of $2.60. |

| (2) | In accordance with SEC rules, amounts in this column reflect the aggregate grant date fair value of restricted stock units (“RSUs”) granted during 2024 computed in accordance with ASC 718, rather than the amounts paid or realized by the named individual. We provide information regarding the assumptions used to calculate the grant date fair value of our RSUs in Note 14 to our audited consolidated financial statements filed with our Annual Report on Form 10-K for the year ended December 31, 2024. |

| (3) | As of December 31, 2024, Ms. Griffin held (i) options to purchase 152,826 shares of our common stock, 140,815 of which were vested and exercisable as of such date; and (ii) 31,328 unvested RSUs. |

| (4) | As of December 31, 2024, Dr. Hershberg held (i) options to purchase 145,742 shares of our common stock, 133,731 of which were vested and exercisable as of such date; and (ii) 31,328 unvested RSUs. |

| (5) | As of December 31, 2024, Mr. Neupert held (i) options to purchase 290,742 shares of our common stock, 278,731 of which were vested and exercisable as of such date; and (ii) 31,328 unvested RSUs. |

| (6) | As of December 31, 2024, Dr. Owen held (i) options to purchase 99,204 shares of our common stock, 86,498 of which were vested and exercisable as of such date; and (ii) 32,439 unvested RSUs. |

| (7) | As of December 31, 2024, Dr. Pellini held (